替格瑞洛用于氯吡格雷抵抗的经皮冠状动脉介入患者40例  

Percutaneous Coronary New Platelet Inhibitors Clopidogrel Resistance Ticagrelor for Patients Involved in 40 Cases

作　　者：王星[1] 浦奎[1] 贾忠伟[1] 

机构地区：[1]中国人民解放军第二五四医院,天津300000

出　　处：《中国药业》2015年第15期74-75,共2页China Pharmaceuticals

摘　　要：目的观察氯吡格雷抵抗的经皮冠状动脉介入(PCI)治疗患者采用替格瑞洛治疗的临床效果及安全性。方法选取医院收治的PCI患者80例,均经血栓弹力图(TEG)检查证实为氯吡格雷抵抗,随机分成试验组和对照组,各40例。对照组继续口服硫酸氢氯吡格雷片(75 mg,每日1次),试验组改用口服替格瑞洛片(90 mg,每日2次),同时服用阿司匹林肠溶片(100 mg,每日1次)。两组均连续用药3个月,随访3个月。结果治疗3个月后,对照组血小板计数为(198.21±86.62)×109/L,血小板聚集率为(44.51±8.65)%,二磷酸腺苷最大聚集时间为(63.21±56.21)s,二磷酸腺苷最大聚集率为(35.61±6.95)%,与试验组的(188.54±83.62)×109/L、(36.32±5.63)%、(178.51±89.65)s、(65.12±8.21)%相比,差异均有统计学意义(P<0.05);随访3个月,试验组心血管事件发生率为5.00%,显著低于对照组的22.50%(P<0.05);试验组出血发生率为2.50%,低于对照组的10.00%(P>0.05)。结论替格瑞洛治疗氯吡格雷抵抗的PCI患者,疗效满意,安全性高,值得临床应用。Objective To evaluate the ticagrelor treatment of percutaneous coronary intervention in patients with the clinical effects of clopidogrel resistance. Methods In our hospital percutaneous coronary intervention in patients with 80 cases, patients were selected by the TEG （thrombelastograph） were confirmed as clopidogrel resistance. By randomly selected cases will be divided into experimental and control groups with 40 patients in the control group continued clopidogrel therapy（75 mg / d, for 7 d）, the experimental group received ticagrelor therapy （90 mg, 2 times / d, for 7 d）, aspirin（100 mg, 1 times / d）, for 3 weeks, follow - up 3 months. Results Platelet count was （198. 21 ± 86. 62） ＆#215; 109 / L, platelet aggregation rate （44. 51 ± 8. 65）% , adenosine diphosphate maximum aggregate time （63. 21 ± 56. 21 ） s, the maximum aggregate rate of adenosine diphosphate It was （35. 61 ± 6. 95）% , and the control group （188. 54 ± 83. 62） × 109 / L, （36. 32 ± 5. 63）% , （178. 51 ± 89. 65） s, （65. 12 ± 8. 21）% , the difference was statistically significant（ P〈 0. 05） . Experimental cardiovascular events was 5. 00% , significantly lower than the 22. 50% in the control group（ P〈 0. 05）; the experimental group, bleed-ing was 2. 50% , down from 10. 00% in the control group, but no significant difference between groups（ P〉 0. 05） . Conclusion Tica-grelor therapy after percutaneous coronary intervention in patients with clopidogrel resistance results were satisfactory, safe, large hospitals at all levels learn applications.

关 键 词：替格瑞洛 氯吡格雷抵抗 冠状动脉介入 

分 类 号：R969.4[医药卫生—药理学] R973.2[医药卫生—药学]